CORVUS PHARMACEUTICALS

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

02 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

09 4 2024 15:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

19 3 2024 15:02:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

13 3 2024 15:02:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

12 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

08 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

06 2 2024 15:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

23 1 2024 16:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

09 12 2023 11:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

07 11 2023 15:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

02 11 2023 08:15:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

01 11 2023 18:31:53 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

31 10 2023 15:02:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

06 9 2023 15:05:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

08 8 2023 15:01:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

01 8 2023 07:30:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

06 7 2023 11:59:15 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

29 6 2023 06:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

15 6 2023 06:00:00 提供 Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

31 5 2023 07:30:00 提供 Nasdaq GlobeNewswire